君實生物-B(01877.HK)待財務更新後將及時向上交所申請恢復科創板審核
格隆匯12月9日丨君實生物-B(01877.HK)發佈公告,由於更新財務資料相關的審計工作仍在進行,工作量較大,公司無法在2019年10月31日之前將財務數據更新完畢,故公司於2019年10月31日向上交所提交了《上海君實生物醫藥科技股份有限公司關於首次公開發行股票並在科創板上市中止審核的申請》,待財務數據更新工作完成後,公司將及時向上交所申請恢復審核。
目前,公司首次公開發行股票並在科創板上市申請的審核狀態為“中止”,中止審核期間公司將繼續推進IPO各項工作,相關工作的開展不受中止審核影響。
根據《全國中小企業股份轉讓系統業務規則(試行)》的規定,公司股票將繼續在全國中小企業股份轉讓系統暫停轉讓。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.